Telogen effluvium: understanding diffuse shedding and monitoring regrowth

Diffuse shedding needs a clinical assessment first

The most suggestive feature is an unusual increase in shed hairs, coming from several areas of the head. Hair may lose volume without developing completely bare patches. The scalp usually looks normal, with no visible inflammation or scarring, as described in Malkud’s review (2015).

The amount collected during washing also depends on the interval between washes and the length of the hair. A count on one particular day cannot reliably distinguish normal renewal from a hair disorder. When describing the problem, its starting date, persistence and effect on density are more useful than repeated daily counting.

A GP is an appropriate first contact if shedding worries you or continues. They can examine the scalp and arrange a dermatology assessment when the cause remains uncertain. The NHS recommends seeking medical advice before approaching a commercial hair clinic; alopecia includes several conditions requiring different treatments.

Clearly defined bare areas need a different assessment, discussed in our article on patchy hair loss. Persistent redness, crusting, significant pain or broken hairs should also be reported to the clinician. These findings cannot establish a particular diagnosis at home, but they make a straightforward hair-cycle explanation insufficient.

Looking back at the months before shedding began

Follicles move through growth, transition and rest before releasing the hair. During telogen effluvium, more hairs reach this later part of the hair cycle. Shedding may therefore become noticeable after the event that triggered it has already passed.

The delay is often two to three months, although it varies with the circumstances. This timing explains why a resolved infection or an earlier operation is still relevant. It does not prove causation: several events may have occurred close together, and some people have no clearly identifiable trigger (Malkud, 2015).

Before the appointment, gather the dates of illnesses with fever, operations, childbirth, dietary changes and changes to medication during the preceding months. Prescriptions, any existing blood results and a few older photographs can help reconstruct the course. You do not need to decide which event caused the shedding before seeking an assessment.

Physical and hormonal circumstances

An infection with fever, major surgery or rapid weight loss may precede telogen effluvium. After childbirth, changes in the hair cycle contribute to delayed shedding: more hairs had remained in the growth phase during pregnancy. This common explanation should still be reassessed if the course seems unusual or other symptoms develop.

A thyroid disorder may also contribute. The clinician considers medical history and associated symptoms when choosing investigations. Shedding around the menopause, after stopping hormonal contraception or during another hormonal transition does not, by itself, establish a need for hormone treatment.

Diet, medicines and emotional stress

Marked calorie restriction or inadequate protein intake can disrupt hair renewal. Iron deficiency is another possibility to consider in context, particularly with blood loss or reduced dietary intake. The consultation should distinguish a genuine nutritional need from an assumption based solely on shedding.

Some medicines can alter the hair cycle. Give the prescriber a complete list of products you take, including supplements, with their starting dates and any recent changes. Changes to prescribed medicines should be agreed with that professional, after considering the treatment’s purpose and its possible relationship to the symptoms.

Major emotional stress may contribute to the onset, while hair loss itself can increase anxiety. It would therefore be misleading to attribute shedding to stress simply because someone is distressed at an appointment. Psychological support can accompany the assessment and help during recovery, alongside investigation of other contributing factors.

What the examination and blood tests can establish

The examination compares hair density and appearance across different scalp regions. The clinician looks for findings such as breakage, inflammation or variation in hair-shaft thickness. Trichoscopy, examination using a magnifying device, can clarify these features and help when more than one type of hair loss is possible.

A gentle hair-pull test during the appointment may demonstrate active shedding. Its result depends partly on the timing of the examination and recent washing, so it cannot establish the whole diagnosis. A biopsy is reserved for selected uncertain cases, for example when another disorder needs to be distinguished from telogen effluvium (Malkud, 2015).

Choosing investigations to suit the individual

A full blood count, ferritin measurement to assess iron stores or thyroid testing may be useful according to the clinical history. Further investigations depend on dietary habits, symptoms and initial results. The aim is to identify an abnormality that can be addressed, with a clinician interpreting the findings.

Research does not support the idea that one particular deficiency explains every case. In 2024, Durusu Turkoglu and colleagues compared 90 women with chronic telogen effluvium and 90 female controls. They found no statistically significant difference between the groups in ferritin or vitamin D, although some other measurements differed.

A retrospective study published in 2025 included 2,851 female patients and recorded low ferritin in 1,123 of the 2,413 patients with an available result. This describes patients attending one particular centre; it establishes neither that iron deficiency explains every episode nor that supplementation restores hair in every patient (Karakoyun et al., 2025).

These studies support an individual assessment. A confirmed deficiency deserves appropriate management and investigation of its cause, but they cannot establish a ferritin target that ensures regrowth. Ordering an extensive panel independently or taking several supplements can complicate interpretation without addressing the actual cause.

Managing the condition during recovery

Management depends on what the assessment identifies. It may involve correcting a nutritional deficiency, treating thyroid disease or reviewing a suspected medicine with its prescriber. After a single trigger has passed, monitoring with a clear explanation may be sufficient; continued shedding for a time does not necessarily mean that this approach has failed.

Everyday care that respects the hair

Adequate meals containing varied sources of protein and iron help meet normal nutritional needs. Dietary support may be useful when eating is restricted, a digestive condition is present or maintaining food intake is difficult. Supplement requirements should be assessed individually; a randomly chosen hair supplement cannot substitute for understanding the findings.

Biotin and multivitamin mixtures lack sufficient evidence to support routine treatment of telogen effluvium in people without an identified deficiency. Biotin can also interfere with certain laboratory tests, so tell the clinician if you take it before blood sampling. Durusu Turkoglu et al. (2024) discuss these limitations and the reasons to avoid indiscriminate micronutrient prescriptions.

Shampooing and gentle detangling mainly maintain scalp hygiene and limit damage to the hair fibre. A product that makes hair feel softer or look fuller has not necessarily changed its growth cycle. If a product causes irritation, seek advice before continuing it or adding further applications.

Minoxidil requires a discussion of the evidence

Topical minoxidil has been investigated to encourage growth, but its value in telogen effluvium is less established than in pattern hair loss. A trial published in 2025 followed 12 adults for a planned 24 weeks and reported improvement in some hair measurements. It was open-label and had no control group, making it impossible to clearly separate the product’s effect from spontaneous recovery.

Two participants left the trial, including one with contact dermatitis, and the study received industry funding. Its authors describe the treatment as off-label and call for stronger research. The findings therefore cannot establish faster regrowth or justify recommending the product to everyone with diffuse shedding (Ohyama et al., 2025).

Any decision to use it should follow a medical diagnosis and a discussion of tolerability. Irritation or a temporary increase in shedding can occur, for example. Injections, PRP and devices marketed as regenerative should likewise not be regarded as established treatments for telogen effluvium merely because results have been reported in another form of alopecia.

Monitoring regrowth and reassessing persistent shedding

Reduced shedding and restored volume are separate milestones. With acute telogen effluvium, shedding often eases over three to six months, while visible recovery takes longer. New hairs need to gain length before they contribute fully to coverage; the timetable varies between individuals (Malkud, 2015; Ohyama et al., 2025).

A few photographs taken at spaced intervals, with comparable lighting and styling, can complement clinical follow-up. They help show a trend without placing too much emphasis on variation between washes. The clinician can also compare the initial examination with signs of regrowth and agree when to review progress.

Shedding lasting more than six months is described as chronic telogen effluvium. It may fluctuate, and an underlying cause is not always found despite a careful assessment. This duration warrants reviewing the case; it does not establish an inevitable hidden deficiency or progressive destruction of all the follicles.

Androgenetic alopecia may coexist with telogen effluvium. Miniaturisation, which produces finer hairs, then contributes to reduced coverage. A shedding episode can reveal thinning that was previously less noticeable. The two forms of hair loss involve different mechanisms.

Follow-up should also consider effects on sleep, daily activities and self-esteem. Camouflage options can be discussed if you want them, with no expectation that you must hide hair loss. Talking to a GP can help you access suitable support, even when the examination is reassuring about the potential for regrowth (NHS, 2024).

Making hair-restoration decisions after diagnosis

A transplant redistributes follicles and does not correct the cycle disturbance responsible for isolated telogen effluvium. Temporarily reduced density is therefore insufficient grounds for surgery. Our hair transplant guide explains how suitability is assessed, taking account of the type of thinning and the condition of the donor supply.

If another form of alopecia remains after reassessment, medical and, in selected cases, surgical options can be discussed on their own indications. At Body Expert, any enquiry about a hair transplant in Istanbul should rest on a clear diagnosis. During telogen effluvium, the priorities are to understand the shedding, address relevant causes and assess the course before deciding on lasting restoration.

Sources

Malkud, S. (2015). Telogen effluvium: A review. Journal of Clinical and Diagnostic Research, 9(9), WE01-WE03. Full text.

Durusu Turkoglu, I. N., Turkoglu, A. K., Soylu, S., Gencer, G., & Duman, R. (2024). A comprehensive investigation of biochemical status in patients with telogen effluvium: Analysis of Hb, ferritin, vitamin B12, vitamin D, thyroid function tests, zinc, copper, biotin, and selenium levels. Journal of Cosmetic Dermatology, 23(12), 4277-4284. Full text.

Karakoyun, Ö., Ayhan, E., & Yıldız, İ. (2025). Retrospective review of 2851 female patients with telogen effluvium: A single-center experience. Journal of Cosmetic Dermatology, 24(2), e70037. Full text.

Ohyama, M., Irisawa, R., Uchiyama, M., Mori, M., Aoki, K., Ueda, Y., & Fujita, T. (2025). Use of 5% topical minoxidil application for telogen effluvium: An open-label single-arm clinical trial. The Journal of Dermatology, 52(9), 1351-1359. Full text.

National Health Service. (2024, January 24). Hair loss. Public information on assessment and support.